Biosynth Carbosynth Acquires Pepscan

Biosynth Acquires Pepceuticals to Add Multi-Kilogram GMP Peptide Manufacturing

September 25, 2023

Pharmaceuticals

Biosynth has acquired Pepceuticals, a UK-based specialist in synthetic peptides with multi-kilogram GMP and fill-finish capabilities. The deal expands Biosynth’s peptide division and enables end-to-end support from discovery through clinical trials to commercial supply.

KKR-backed Biosynth Carbosynth Acquires vivitide; Ampersand Rolls Over Stake

March 17, 2022

Biotechnology

KKR has invested in Biosynth Carbosynth through its Health Care Strategic Growth Fund II, and Biosynth Carbosynth has acquired vivitide, a global provider of custom peptides and antibody services. Existing owner Ampersand Capital Partners rolled over its entire stake and will be a substantial minority shareholder in the combined global life‑sciences reagents and custom synthesis platform to accelerate geographic expansion, broaden capabilities, and expand the product portfolio.

Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities

July 11, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.

Biosynth Carbosynth Acquires Aalto Bio Reagents

May 26, 2022

Biotechnology

Biosynth Carbosynth, a Swiss life‑sciences supplier, has acquired Aalto Bio Reagents, a Dublin‑based developer and provider of biological materials for in‑vitro diagnostics (IVD) and vaccine development. The deal strengthens Biosynth’s IVD and vaccine product portfolio and expands its capabilities to serve diagnostics and vaccine development customers worldwide.

Ampersand Capital Partners Acquires Peptides International and Merges It with New England Peptide

December 16, 2019

Biotechnology

Ampersand Capital Partners has acquired Peptides International and merged it into its existing portfolio company, New England Peptide, creating a combined provider of custom and catalog peptide synthesis services. The transaction is an add-on to Ampersand’s New England Peptide platform to expand scale, capabilities, and customer relationships across pharmaceutical, biotech and academic markets.

Biosynth Acquires Cambridge Research Biochemicals (CRB)

May 9, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical materials to the life science industry, has acquired Cambridge Research Biochemicals (CRB), a UK-based independent producer of custom peptides and antibody tools. The acquisition expands Biosynth's peptide and antibody capabilities in Europe, adding expertise in complex peptide chemistry, fluorescent dye labelling and custom antibody generation to its existing operations.